[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[e-drug] NCD Alliance 'Access to Essential Medicines and Technologies for NCDs' briefing paper

  • From: "Kathy Annette Glück" <kgluck@ncdalliance.org>
  • Date: Thu, 25 Aug 2011 19:10:48 +1000

E-DRUG: NCD Alliance launches 'Access to Essential Medicines and
Technologies for NCDs' briefing paper

Dear All,

I am happy to announce that we have launched the NCD Alliance 'Access to
Essential Medicines and Technologies for NCDs' briefing paper. This
publication could not have been made possible without the dedication and
expertise of the Working Group (WG). On behalf of the NCD Alliance, I
thank you for your efforts and collaboration. A special thanks goes to
the WG Chair, Cécile Macé, for her professionalism and leadership.

The chapter was written by Shanthi Pal from the
Department of Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Alex Dodoo from the University of Ghana Medical School in Ghana, Aukje Mantel from Utrecht University in the Netherlands and Sten Olsson from the Uppsala Monitoring Centre in Sweden.

To download the chapter please go to the URL http://apps.who.int/medicinedocs/en/m/abstract/Js18771en/
that includes the following abstract.

Pharmacovigilance (PV) aims to improve patient safety through the detection, assessment, understanding and prevention of adverse effects and other drug related problems;

PV, as a discipline, has seen tremendous growth over the past decade, but in response to different needs and priorities worldwide. While 'high-burden diseases' have been the focus in some settings, elsewhere this growth has been driven by a demand for transparency and access to information;

Recent years have seen a trend towards Good Pharmacovigilance Practice (GPP), particularly in industrialized countries to assure standards and innovations in the collection, management, analysis and use of medicine safety information -with patient safety as the ultimate objective;
- Many resource-limited countries will require additional support (technical and financial) to build PV capacity to effective levels;
- Despite 40 years of PV, patients worldwide continue to be affected by preventable harm from medicines. It is important to analyse and learn from these events;
- For PV to be effective there is a need for timely and responsible communication of the available evidence, involving all stakeholders;
- Many new PV initiatives are being undertaken. But it is important that these efforts are not duplicated and that scarce resources are used wisely.

For more information on other chapters go to http://www.who.int/medicines/areas/policy/world_medicines_situation/en/index.html
or the Table of Contents at http://www.who.int/medicines/areas/policy/world_medicines_situation/wmsr_table/en/index.html

The briefing paper has been launched via the following web-based

NCD Alliance homepage:* http://www.ncdalliance.org/

*News page*: http://www.ncdalliance.org/node/3485

*Working Group page:* http://www.ncdalliance.org/node/3439

It has been a pleasure working with you and I look forward to any
collaboration in the future.

Kind regards,

Kathy Glück
Program Coordinator-The NCD Alliance
c/o UICC, 62 route de Frontenex
1207 Geneva, Switzerland
Office: +41 (0)22 809 18 45
Mobile: +41 (0)77 468 55 80
E-mail: KGluck@ncdalliance.org <mailto:KGluck@ncdalliance.org>